The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care

被引:262
作者
Casper, C
机构
[1] Univ Washington, Sch Med, Dept Med, Div Infect Dis, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA
关键词
lymphoproliferative disease; Castleman disease; angiofollicular lymph node hyperplasia; human herpesvirus 8;
D O I
10.1111/j.1365-2141.2004.05311.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fifty years ago, Dr Benjamin Castleman first described the unusual lymphoproliferative disorder that now bears his name. Over the subsequent decades, astute clinical and pathologic observations coupled with clever molecular biologic research have increased our understanding of the aetiology of Castleman disease (CD). This article proposes three broad CD variants based on both distinctive histopathology and clinical behaviour. The pivotal roles of infection with human herpesvirus 8 and interleukin-6 production in the development of CD are emphasized. Finally, the natural history of CD and the myriad of therapeutic options are reviewed in the context of a unified model of CD pathophysiology, and continued areas of uncertainty are discussed.
引用
收藏
页码:3 / 17
页数:15
相关论文
共 104 条
[71]  
MURRAY PG, 1995, HEMATOL PATHOL, V9, P17
[72]   THE CROW-FUKASE SYNDROME - A STUDY OF 102 CASES IN JAPAN [J].
NAKANISHI, T ;
SOBUE, I ;
TOYOKURA, Y ;
NISHITANI, H ;
KUROIWA, Y ;
SATOYOSHI, E ;
TSUBAKI, T ;
IGATA, A ;
OZAKI, Y .
NEUROLOGY, 1984, 34 (06) :712-720
[73]   Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-α levels [J].
Newsom-Davis, T ;
Bower, M ;
Wildfire, A ;
Thirlwell, C ;
Nelson, M ;
Gazzard, B ;
Stebbing, J .
LEUKEMIA & LYMPHOMA, 2004, 45 (09) :1939-1941
[74]   Antiviral drug susceptibility of human herpesvirus 8 [J].
Neyts, J ;
DeClercq, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2754-2756
[75]   Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease [J].
Nishi, J ;
Arimura, K ;
Utsunomiya, A ;
Yonezawa, S ;
Kawakami, K ;
Maeno, N ;
Ijichi, O ;
Ikarimoto, N ;
Nakata, M ;
Kitajima, I ;
Fukushige, T ;
Takamatsu, H ;
Miyata, K ;
Maruyama, I .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (03) :482-485
[76]   Improvement In Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy [J].
Nishimoto, N ;
Sasai, M ;
Shima, Y ;
Nakagawa, M ;
Matsumoto, T ;
Shirai, T ;
Kishimoto, T ;
Yoshizaki, K .
BLOOD, 2000, 95 (01) :56-61
[77]   Low dose interferon-a therapy for HIV-associated multicentric Castleman's disease [J].
Nord, JA ;
Karter, D .
INTERNATIONAL JOURNAL OF STD & AIDS, 2003, 14 (01) :61-62
[78]   MOLECULAR-GENETIC, CYTOGENETIC, AND IMMUNOPHENOTYPIC ANALYSES IN CASTLEMANS DISEASE OF THE PLASMA-CELL TYPE [J].
OHYASHIKI, JH ;
OHYASHIKI, K ;
KAWAKUBO, K ;
SERIZAWA, H ;
ABE, K ;
MIKATA, A ;
TOYAMA, K .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 101 (03) :290-295
[79]   Absence of gallium uptake in unicentric and multicentric Castleman's disease [J].
Okamoto, I ;
Iyonaga, K ;
Fujii, K ;
Mori, T ;
Yoshioka, M ;
Kohrogi, H ;
Matsumoto, M ;
Suga, M .
INTERNAL MEDICINE, 2003, 42 (08) :735-739
[80]   High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients [J].
Oksenhendler, E ;
Carcelain, G ;
Aoki, Y ;
Boulanger, E ;
Maillard, A ;
Clauvel, JP ;
Agbalika, F .
BLOOD, 2000, 96 (06) :2069-2073